Answers are grounded in this paper and cite their sources.
Ó 2007 Scienta Healthcare Education Ò 1 levels above 1% [10,[13][14][15][16][17][18][19][20][21].Nonetheless, surveys of international practice patterns [22,23] and statistics from the Universal Data Collection Programme [24] indicate that the majority of patients with severe FVIII deficiency continue to receive on-demand therapy.In an effort to optimize outcomes in patients with severe haemophilia A through increasing the use of prophylaxis, a panel of clinicians from haemophilia treatment centres (HTCs) in North America convened in Miami, Florida, on January 27-28, 2007, to review the current state of knowledge about joint-protective therapeutic approaches and from this derive best treatment strategies.We hope that the information presented in this supplement, which summarizes our review of the literature and subsequent discussions and recommendations, will help physicians and their staffs develop protocols for the use of prophylaxis in children, adolescents and adults with severe haemophilia A.We appreciate the opportunity to be guest editors of this CME supplement to Haemophilia and to work with our colleagues from the United States and Canada.
No takes yet. Share an insight, caveat, or question.
Pipe et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: